Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serum uric acid and multiple sclerosis.

S Sotgiu1, M Pugliatti, A Sanna

  • 1Institute of Clinical Neurology, Faculty of Medicine, University of Sassari, Viale San Pietro 10, I-07100 Sassari, Italy.

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|January 22, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>HER-2</i> gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study.

ESMO gastrointestinal oncology·2026
Same author

Climate-related challenges to brain health: A European perspective review.

Revue neurologique·2025
Same author

Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial.

ESMO open·2025
Same author

Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study.

ESMO open·2023
Same author

A multicentre study on spontaneous in-cage activity and micro-environmental conditions of IVC housed C57BL/6J mice during consecutive cycles of bi-weekly cage-change.

PloS one·2022
Same author

NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.

European review for medical and pharmacological sciences·2021

Multiple sclerosis patients show lower serum uric acid (UA) levels, suggesting a primary deficiency in this antioxidant. This finding supports further research into UA

Area of Science:

  • Neuroimmunology
  • Oxidative Stress Research
  • Biochemistry

Background:

  • Multiple sclerosis (MS) is associated with reduced serum uric acid (UA), an endogenous antioxidant.
  • The cause of low UA in MS—primary deficiency versus secondary reduction due to antioxidant activity—remains unclear.

Purpose of the Study:

  • To investigate whether low serum UA levels in MS patients are a primary deficiency or a consequence of increased oxidative stress.
  • To explore the relationship between UA levels and MS disease characteristics.

Main Methods:

  • Serum UA levels were measured in 124 MS patients and 124 age- and sex-matched controls with other neurological diseases.
  • MS patients were stratified by disease activity (clinical and MRI), duration, disability, and course for comparative analysis.

Related Experiment Videos

Main Results:

  • MS patients exhibited significantly lower serum UA levels compared to controls (p=0.001).
  • No significant correlation was found between UA levels and MS disease activity, duration, disability, or course.

Conclusions:

  • The findings suggest that reduced UA in MS is likely a primary, constitutive loss of antioxidant protection.
  • Further research is warranted to elucidate the pathogenetic role of UA in MS for potential therapeutic strategies.